Peptides in skincare: an evidence map, not a promise list

Peptides are the current default answer to “what should I use after retinol,” and the shelf has outrun the data. The category is not empty of science — far from it — but the science is uneven in a way that marketing flattens. Peptides are a family of dozens of molecules with three different working theories, and the evidence for those theories is not interchangeable. Reading the label well starts with knowing which family a product is actually selling.

Family one: signal peptides, the strongest case

Signal peptides — the Matrixyl family, palmitoyl pentapeptides and their successors — are short chains designed to mimic fragments of collagen breakdown, on the theory that skin reads the fragment as a repair cue and upregulates collagen-related activity. This is the best-evidenced corner of the category. Published clinical trials, mostly small and industry-sponsored, show measurable improvement in fine lines over roughly two to four months of use.

The fair summary: a real, reproducible-direction signal, at a magnitude that is modest. Nothing in the signal-peptide literature approaches the effect sizes reported for retinoids, which is why the family works better as a retinoid companion than as a stand-in for one.

Family two and three: copper and the “topical Botox” claim

Carrier peptides, copper peptides foremost, deliver a trace metal involved in wound repair. The science here is genuinely interesting and genuinely contested: copper is biologically central to skin remodeling, but published work has focused on the raw material, and skeptics argue that the chelating formula context and stability questions blunt the story. Copper peptide products also carry a practical warning — many formulators avoid pairing them with direct acids or strong vitamin C in the same routine, citing oxidation and irritation concerns rather than data.

Neuro-transmitter-inhibiting peptides — Argireline and relatives, marketed as topical wrinkle relaxers — have the weakest case. The mechanism borrows credibility from injectable neurotoxins that work at vastly different doses and depths. Published trials run small and short, and independent replication is scarce. If a product’s pitch leans on the word “Botox-like,” the pitch has outrun the citation.

Reading a peptide label

Three label-reading moves do most of the work. First, identify the family: look for “palmitoyl” prefixes and pentapeptide/tetrapeptide names for signal peptides, “copper tripeptide-1” for carrier peptides, and “acetyl hexapeptide-8” for the Argireline group. Trade names like Matrixyl will not appear in the ingredient list at all — INCI rules require the generic name, so the branded raw material hides behind it. Second, treat position as a concentration cue: peptides are typically active around the low single-digit percents, so a peptide name appearing after preservatives is a dusting. Third, discount the count: “contains 12 peptides” is a marketing metric, not an efficacy one, as our niacinamide concentration guide argues in a parallel case.

What remains unknowable from the label is the actual concentration. Brands are not required to disclose it, and few volunteer it. That opacity is the category’s structural weakness, and the reason we treat the family as a supporting purchase rather than the center of a routine. Our layering guide covers where peptide serums sit in sequence.

Where peptides belong in a routine

If you want the most defensible peptide purchase, look for a signal-peptide formula with the peptide named high on the list and a brand that publishes its trials’ duration. Keep expectations calibrated to the data: gradual fine-line softening over months, no overnight anything. The family is a fine supporting act. The evidence simply does not cast it as a lead.